Status:
COMPLETED
Effect of Adjunctive Treatment With Arestin on the Subgingival Microflora in Patients With Moderate to Advanced Periodontitis
Lead Sponsor:
OraPharma
Conditions:
Periodontitis
Eligibility:
All Genders
30-65 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to measure the antimicrobial effects of Arestin in subjects with moderate to advanced periodontal disease
Eligibility Criteria
Inclusion
- Generalized moderate to advanced chronic periodontitis, five sites with probing depths of \>5 mm in 5 non-adjacent interproximal spaces, excluding the distal of terminal teeth, at least 16 teeth excluding 3rd molars and implants
Exclusion
- Allergy to tetracycline
- Subjects with aggressive periodontitis
- Acute necrotizing ulcerative gingivitis, or gross decay
- Systemic conditions which could influence the course of periodontal disease (i.e, diabetes, autoimmune disease, etc)
- Individuals requiring prophylactic antibiotics
- Any periodontal therapy within the previous 3 months (excluding maintenance therapy)
- Systemic or local antibiotic therapy within three months
Key Trial Info
Start Date :
January 1 2004
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
128 Patients enrolled
Trial Details
Trial ID
NCT00371332
Start Date
January 1 2004
Last Update
September 25 2006
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Los Angeles, California, United States
2
Baltimore, Maryland, United States
3
Boston, Massachusetts, United States
4
Buffalo, New York, United States